Dr Robert Chu Du Lee, MD | |
192 Prospect Ave, Hackensack, NJ 07601-2204 | |
(201) 996-0232 | |
(201) 996-0095 |
Full Name | Dr Robert Chu Du Lee |
---|---|
Gender | Male |
Speciality | Internal Medicine |
Experience | 36 Years |
Location | 192 Prospect Ave, Hackensack, New Jersey |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1497830293 | NPI | - | NPPES |
01732214 | Medicaid | NY |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207RP1001X | Internal Medicine - Pulmonary Disease | 180837 (New York) | Secondary |
207RP1001X | Internal Medicine - Pulmonary Disease | 25MA06687400 (New Jersey) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Hackensack University Medical Center | Hackensack, NJ | Hospital |
Entity Name | Hackensack Meridian Health Medical Group - Specialty Care Pc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1215989249 PECOS PAC ID: 9133032519 Enrollment ID: O20031111000524 |
News Archive
How would you rate your own physical fitness? Is it good, satisfactory or maybe even poor? Surprisingly, your answer may reveal your future risk of getting dementia.
BeaconEquity.com announces an investment report featuring Antigenics Inc. The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.
Scientists seeking new ways to fight maladies ranging from arthritis and osteoporosis to broken bones that won't heal have cleared a formidable hurdle, pinpointing and controlling a key molecular player to keep stem cells in a sort of extended infancy.
In a new perspective piece published in the Feb. 5 issue of Science, pharmacologist Namandje Bumpus, Ph.D. - who recently became the first African American woman to head a Johns Hopkins University School of Medicine department, and is the only African American woman leading a pharmacology department in the country - outlines the molecular origins for differences in how well certain drugs work among distinct populations.
PolyMedix, Inc. has received a notice of no objection from Health Canada for the Company's Clinical Trial Application ("CTA") for its defensin mimetic antibiotic compound, PMX-30063. This notice of no objection allows for the initiation of human clinical studies in Canada. PMX-30063 is the first defensin mimetic antibiotic compound cleared to enter human clinical trials for systemic use, representing an entirely new class of antibiotic drugs.
› Verified 6 days ago
Entity Name | American Medical Group |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1497912588 PECOS PAC ID: 4486717733 Enrollment ID: O20090113000150 |
News Archive
How would you rate your own physical fitness? Is it good, satisfactory or maybe even poor? Surprisingly, your answer may reveal your future risk of getting dementia.
BeaconEquity.com announces an investment report featuring Antigenics Inc. The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.
Scientists seeking new ways to fight maladies ranging from arthritis and osteoporosis to broken bones that won't heal have cleared a formidable hurdle, pinpointing and controlling a key molecular player to keep stem cells in a sort of extended infancy.
In a new perspective piece published in the Feb. 5 issue of Science, pharmacologist Namandje Bumpus, Ph.D. - who recently became the first African American woman to head a Johns Hopkins University School of Medicine department, and is the only African American woman leading a pharmacology department in the country - outlines the molecular origins for differences in how well certain drugs work among distinct populations.
PolyMedix, Inc. has received a notice of no objection from Health Canada for the Company's Clinical Trial Application ("CTA") for its defensin mimetic antibiotic compound, PMX-30063. This notice of no objection allows for the initiation of human clinical studies in Canada. PMX-30063 is the first defensin mimetic antibiotic compound cleared to enter human clinical trials for systemic use, representing an entirely new class of antibiotic drugs.
› Verified 6 days ago
Mailing Address | Practice Location Address |
---|---|
Dr Robert Chu Du Lee, MD Po Box 1715, South Hackensack, NJ 07606-0315 Ph: (201) 880-0700 | Dr Robert Chu Du Lee, MD 192 Prospect Ave, Hackensack, NJ 07601-2204 Ph: (201) 996-0232 |
News Archive
How would you rate your own physical fitness? Is it good, satisfactory or maybe even poor? Surprisingly, your answer may reveal your future risk of getting dementia.
BeaconEquity.com announces an investment report featuring Antigenics Inc. The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.
Scientists seeking new ways to fight maladies ranging from arthritis and osteoporosis to broken bones that won't heal have cleared a formidable hurdle, pinpointing and controlling a key molecular player to keep stem cells in a sort of extended infancy.
In a new perspective piece published in the Feb. 5 issue of Science, pharmacologist Namandje Bumpus, Ph.D. - who recently became the first African American woman to head a Johns Hopkins University School of Medicine department, and is the only African American woman leading a pharmacology department in the country - outlines the molecular origins for differences in how well certain drugs work among distinct populations.
PolyMedix, Inc. has received a notice of no objection from Health Canada for the Company's Clinical Trial Application ("CTA") for its defensin mimetic antibiotic compound, PMX-30063. This notice of no objection allows for the initiation of human clinical studies in Canada. PMX-30063 is the first defensin mimetic antibiotic compound cleared to enter human clinical trials for systemic use, representing an entirely new class of antibiotic drugs.
› Verified 6 days ago
Dr. Sean Shabbir Sadikot, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 20 Prospect Ave Ste 707, Hackensack, NJ 07601 Phone: 551-996-2211 Fax: 551-996-5727 | |
Mr. Angel J Mulkay, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 493 Essex Avenue, Hackensack, NJ 07601 Phone: 201-996-9244 Fax: 201-601-0995 | |
Dr. Morris Samuel Friedman, DO Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 52 1st St, Hackensack, NJ 07601 Phone: 201-342-0066 Fax: 201-342-0079 | |
Dr. David Serur, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 20 Prospect Ave Ste 406, Hackensack, NJ 07601 Phone: 551-996-2608 Fax: 551-996-0826 | |
Jerome F Levine, M.D. Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 20 Prospect Ave, Suite 507, Hackensack, NJ 07601 Phone: 201-487-4088 | |
Dr. Noa Biran, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 92 2nd St, Hackensack, NJ 07601 Phone: 551-996-8704 Fax: 551-996-0582 | |
Naresh Chanderi, MD Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 344 Prospect Ave, Hackensack, NJ 07601 Phone: 201-342-4233 Fax: 201-342-4840 |